Transdermal testosterone, dosed at about a tenth of the male dose, has the strongest clinical evidence for directly boosting libido in women on hormone replacement therapy. But “best” depends on what is driving your low desire in the first place. Vaginal dryness making sex painful is a different problem from a brain that simply stopped sending the “want” signal, and the hormonal fix for each looks quite different. The route you take your estrogen, whether you add testosterone or a compound like tibolone, and even the type of progestogen in your regimen all shift the equation.
Why the Way You Take Estrogen Matters More Than the Estrogen Itself
One of the least intuitive findings in this area is that estrogen can actually work against libido depending on how you take it. Oral estrogen passes through the liver first, and when it does, it stimulates the production of a protein called sex hormone-binding globulin (SHBG). SHBG latches onto testosterone in your bloodstream and makes it inactive. In a two-year study comparing oral conjugated estrogen with transdermal estrogen, women on the oral form had significantly elevated SHBG levels by the end of the first year, while women using transdermal estrogen showed no change in SHBG at all.1PubMed. Long-term effects of continuous oral and transdermal estrogen replacement therapy on sex hormone binding globulin and free testosterone levels The practical consequence: oral estrogen can quietly suppress the small amount of testosterone your body still makes, which is the hormone most closely tied to sexual desire.
The Kronos Early Estrogen Prevention Study (KEEPS), one of the more carefully designed menopause trials, found exactly this pattern. Women randomized to oral conjugated estrogen saw no improvement in desire or arousal compared to placebo, while the association between oral estrogen, rising SHBG, declining free androgens, and flat libido was clear.2JAMA Internal Medicine. Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause: Ancillary Study of the Kronos Early Estrogen Prevention Study (KEEPS) If you are already on oral estrogen and feel like your desire has flatlined or worsened, switching to a patch, gel, or spray may help simply by getting the liver out of the equation.
Estrogen With or Without Something Else
A broad look at the research finds that estrogen-only therapy can increase sexual desire, but only when it pushes circulating estradiol levels high enough to approximate what the body produces around ovulation. Four out of five studies reviewed in a comparative analysis found that estrogen regimens reaching those levels improved desire in postmenopausal women. However, when testosterone was added on top of estrogen, the effect on desire was stronger and more consistent: ten out of twelve studies found that adding testosterone above physiological levels enhanced estrogen’s effect on sexual wanting.3PubMed Central. Increasing women’s sexual desire: The comparative effectiveness of estrogens and androgens
A recent meta-analysis that pooled results across many trials put this in more measured terms. Estrogen therapy alone showed a small benefit on composite sexual function scores. Estrogen combined with a progestogen showed a similar small and statistically uncertain benefit. Tibolone and selective estrogen receptor modulators each showed small benefits too.4PubMed Central. Hormone therapy for sexual function in perimenopausal and postmenopausal women: a systematic review and meta-analysis update The honest takeaway is that standard HRT regimens (estrogen, with or without a progestogen) improve sexual function a little, but for women whose primary complaint is desire itself, estrogen alone often is not enough.
Testosterone for Women With Low Desire
The clearest evidence for a hormone that directly targets desire points to testosterone. In large randomized trials of postmenopausal women, transdermal testosterone at a dose of 300 micrograms per day significantly improved sexual desire and reduced the distress associated with hypoactive sexual desire disorder (HSDD).5PubMed. Testosterone therapy for female sexual dysfunction: a systematic review of the literature demonstrating outcomes in premenopausal and postmenopausal women The word “modestly” comes up repeatedly in clinical guidelines, and it is worth being honest about what that means in practice. In one landmark trial of over 800 women not taking estrogen, those on the 300-microgram daily patch reported about two extra satisfying sexual episodes per month compared to roughly one extra in the placebo group. Both doses of testosterone (300 and 150 micrograms) were associated with increases in desire and decreases in personal distress about their sex life.6PubMed. Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen
Two extra satisfying encounters a month may sound underwhelming on paper, but for women who have experienced months or years of near-zero desire accompanied by real emotional distress, that shift can feel meaningful. Clinical guidelines emphasize that testosterone is modestly beneficial in appropriately selected postmenopausal women with distressing low desire.7PubMed. Testosterone for the Treatment of Hypoactive Sexual Desire Disorder in Perimenopausal and Postmenopausal Women “Appropriately selected” matters here: testosterone is not a general libido enhancer for anyone who wants more desire. It works best when low desire is the central problem and other causes (relationship issues, depression, medication side effects) have been considered.
How Testosterone Is Dosed for Women
No testosterone product is currently FDA-approved specifically for women, which creates a practical headache. Doctors prescribe male-formulated products at adjusted doses. The standard approach is to start at roughly one-tenth the recommended male starting dose. For a 1% testosterone gel marketed to men, that translates to about 5 milligrams per day (one tube or packet every ten days rather than every day). The dose can be increased to about 10 milligrams per day based on blood levels and symptom response.8PubMed Central. The clinical management of testosterone replacement therapy in postmenopausal women with hypoactive sexual desire disorder: a review Transdermal delivery (patches, gels, creams, or sprays) is preferred because it avoids the liver-first-pass problem and allows the dose to be adjusted gradually to keep blood levels within the normal female range.
The main side effects at these doses are androgenic: acne and increased hair growth.9Fertility and Sterility. Safety of testosterone treatment in postmenopausal women These are generally mild and dose-dependent, meaning they tend to resolve if the dose is lowered. The bigger concern for many women has been whether long-term testosterone use raises cardiovascular or breast cancer risk. A large claims-database analysis comparing women on testosterone therapy with matched controls found no increase in cardiovascular events, blood clots, or breast cancer. In fact, the testosterone group had lower rates across most of those outcomes.10PubMed. Testosterone therapy in females is not associated with increased cardiovascular or breast cancer risk: a claims database analysis That is reassuring, though database studies have their limitations and longer prospective trials would strengthen the case.
Tibolone and Its Dual Action
Tibolone is a synthetic steroid widely prescribed in Europe, Australia, and parts of Asia (though not available in the United States). It breaks down in the body into metabolites with estrogenic, progestogenic, and androgenic activity, making it something of a three-in-one HRT. In clinical testing, tibolone significantly increased sexual desire, the frequency of feeling sexually aroused, and the frequency of sexual fantasies compared to placebo.11PubMed. The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women The meta-analysis mentioned earlier confirmed a small but positive effect on composite sexual function scores.4PubMed Central. Hormone therapy for sexual function in perimenopausal and postmenopausal women: a systematic review and meta-analysis update
Because tibolone does not raise SHBG the way oral estrogen does, it avoids suppressing free testosterone. For women who want a single pill that addresses vasomotor symptoms (hot flashes, night sweats), vaginal dryness, and desire all at once, tibolone is a legitimate option where available. Its main limitation is geographic: if you live in the U.S. or Canada, your doctor cannot prescribe it.
When Pain Is the Real Barrier
Sometimes the issue is not desire in the brain but pain during sex that makes desire irrelevant. Vaginal atrophy after menopause causes dryness, thinning of tissue, and pain with intercourse, and it is hard to want something that hurts. In these cases, treating the tissue problem can unlock desire on its own.
Intravaginal prasterone (a form of DHEA inserted as a vaginal suppository) has been shown to improve all six domains of the Female Sexual Function Index, including desire, arousal, lubrication, orgasm, satisfaction, and pain, compared to placebo.12PubMed. Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy Daily vaginal prasterone for twelve weeks reversed many of the cellular changes of atrophy: the severity of painful sex dropped by about 46% over placebo, and vaginal dryness dropped by roughly 42%.13PubMed. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone) Crucially, serum hormone levels stayed within normal postmenopausal ranges, meaning the effects were local rather than systemic.14PubMed. Treatment of moderate to severe dyspareunia with intravaginal prasterone therapy: a review That makes vaginal DHEA appealing for women who cannot or do not want to use systemic hormones but need tissue-level improvement to make sex comfortable again.
Ospemifene, a selective estrogen receptor modulator (SERM) taken as a daily pill, is another option for vulvovaginal atrophy. In a randomized trial, ospemifene at 60 milligrams per day improved overall sexual function scores by week four, with improvement in pain, arousal, and desire. By week twelve, all sexual function domains showed significant improvement over placebo.15Climacteric. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial Ospemifene acts as an estrogen in vaginal tissue while behaving differently in the breast and uterus, which is part of its appeal for women wary of traditional estrogen.
Oral DHEA Supplements and Their Limits
DHEA is sold over the counter in many countries and marketed as a libido booster for both women and men. The intravaginal version discussed above has solid trial data behind it, but the oral, systemic version is a different story. A systematic review of randomized controlled trials in healthy women found the results inconsistent, hampered by small sample sizes and short treatment durations. Studies in women with adrenal insufficiency showed potential improvements in mood and libido, but again the evidence was limited.16Human Reproduction Update. DHEA therapy for women: effect on sexual function and wellbeing In practical terms, oral DHEA supplements are unlikely to be harmful at typical doses, but the evidence that they reliably improve desire is weak enough that most clinical guidelines do not recommend them for that purpose.
Women After Surgical Menopause
Women who have had both ovaries removed face a sharper hormonal cliff than women who go through natural menopause. The ovaries continue producing meaningful amounts of testosterone well into the postmenopausal years, so removing them causes a steep and immediate drop. This makes the libido impact more sudden and often more severe. Several randomized controlled trials have found that transdermal testosterone patches significantly improved HSDD symptoms specifically in postmenopausal women who had undergone bilateral oophorectomy.17PubMed. Androgens in women before and after the menopause and post bilateral oophorectomy: clinical effects and indications for testosterone therapy Some of those same trials found benefit in women after natural menopause, but the response tends to be strongest and most consistent in the surgical group, likely because their testosterone deficit is greatest.
Testosterone for Men With Low Testosterone
The question of HRT and libido is not exclusive to women. Men with genuinely low testosterone levels also experience flagging desire, and testosterone replacement therapy reliably improves it, with one important caveat: the benefit appears to plateau once testosterone levels reach the normal range. Men who already have normal testosterone do not get an additional desire boost from pushing levels higher.18PubMed Central. Testosterone Therapy Improves Erectile Function and Libido in Hypogonadal Men This is a useful reality check for both sexes. Testosterone is not a linear dose-response aphrodisiac. It corrects a deficit. Once the deficit is corrected, more testosterone does not mean more desire, and using supraphysiological doses introduces unnecessary risk.
The Compounded Hormone Question
Because there is no FDA-approved testosterone product for women, many prescriptions are filled by compounding pharmacies that custom-mix hormones. Some clinics also offer compounded “bioidentical” hormone pellets, creams, or troches containing combinations of estradiol, progesterone, testosterone, and DHEA marketed as more natural or safer. The Endocrine Society has been direct about this: there is no evidence that custom-compounded bioidentical hormones carry fewer risks than FDA-approved hormones, and the lack of standardization in compounding introduces real quality-control concerns, including the possibility of overdosing, underdosing, or contamination.19The Journal of Clinical Endocrinology & Metabolism. Compounded Bioidentical Hormones in Endocrinology Practice: An Endocrine Society Scientific Statement
This does not mean compounded testosterone is always a bad choice for women. Given the absence of an approved product, compounding is sometimes the only practical way to get testosterone at an appropriate female dose. The concern is about the marketing framing, not the molecules themselves. “Bioidentical” estradiol from a compounding pharmacy is chemically identical to FDA-approved estradiol. The difference is in how tightly the dose is controlled and tested. If you use a compounded product, periodic blood monitoring is especially important to make sure you are absorbing what you think you are absorbing.
Why Hormones Are Only Part of the Story
Sexual desire in humans is not a simple hormone-level problem. Brain dopamine systems linking the hypothalamus and limbic system form the core of the excitatory network, with contributions from melanocortins, oxytocin, and norepinephrine. Opposing that, opioid, endocannabinoid, and serotonin systems dampen the excitatory signals during periods of sexual inhibition.20The Journal of Sexual Medicine. Pathways of Sexual Desire This means that depression, anxiety, chronic stress, relationship conflict, and even a partner’s sexual difficulties can all suppress desire through pathways that hormones alone cannot fix.21PubMed. Libido: the biologic scenario
SSRIs and SNRIs, among the most commonly prescribed antidepressants, work by increasing serotonin activity, which sits squarely in the inhibitory pathway for desire. A woman taking an SSRI for depression who also has menopausal hormone changes may find that HRT alone barely moves the needle because the medication is actively working against her excitatory system. In those cases, a medication switch, dose adjustment, or addition of a counteracting agent may be more impactful than any hormone change.
The clinical consensus is that a comprehensive approach, evaluating biological factors alongside psychological and relational ones, produces the best results. Well-tailored HRT including androgens in selected cases can reduce the biological causes of low libido, but it works best as one part of a broader strategy rather than a standalone solution.21PubMed. Libido: the biologic scenario A woman who starts testosterone and sees partial improvement may get the rest of the way there by addressing sleep, stress, or a conversation she has been avoiding with her partner.
Matching the Therapy to the Problem
Putting the evidence together, the practical question is less “which HRT is best for libido” and more “what is actually causing the problem.” A rough map:
- Desire itself is gone: Transdermal testosterone at female-appropriate doses has the best trial evidence. It works whether or not you are already on estrogen, though the combination of estrogen plus testosterone tends to be more effective than either alone.
- Sex hurts and desire has followed: Vaginal prasterone (DHEA) or vaginal estrogen can reverse atrophy and pain, and desire often improves as a downstream effect. Ospemifene is an oral alternative.
- On oral estrogen and desire dropped: Switching to transdermal estrogen may help by lowering SHBG and freeing up your remaining testosterone.
- Want a single-agent solution: Tibolone (where available) combines estrogenic, progestogenic, and androgenic effects in one pill and has positive evidence for desire.
- After surgical menopause: The testosterone deficit is typically steeper, and response to transdermal testosterone tends to be strongest in this group.
None of these categories are mutually exclusive. A woman after surgical menopause who also has vaginal atrophy might benefit from both transdermal testosterone and vaginal DHEA. The regimen can be layered, and it often should be, because desire is not a single-switch problem.